Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$30.32 USD
-0.40 (-1.30%)
Updated May 23, 2024 04:00 PM ET
After-Market: $30.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 701 - 718 ( 718 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We See Reduced Competitive Risk as Potential Competitor, Posidur, Misses Phase 3 Endpoint. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Pivotal Trial Data Published in Medical Journal Ahead of Anticipated Launch in January 2012. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Recent Financing Extends Cash Runway Through Commercial Launch and Potential Breakeven. Reiterate OUTPERFORM and Adjusting FV to $16.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Approved For Postsurgical Pain Management and Launch Expected In January 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We Are Optimistic for Potential EXPAREL Approval by the PDUFA Date of this Friday, October 28th. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Data Shows Reduction in Opioid Burden with Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Exparel Use in Plastic Surgery Highlighted at Medical Conference
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Commercial Strategy Progresses with New Marketing and Logistics Agreements Ahead of Important October 28 PDUFA Date for Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of September 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Exparel PDUFA Date Extended by Three Months to October 28th
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Presentation of program-wide safety data for Exparel supports potential FDA approval, in our view.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Financials: Pre-Launch Activities Continue to Progress Ahead of July 28 PDUFA for Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2010 Financials a Non-Event. We See a Major Value Driver Mid-Year with the July 28 PDUFA Date for Exparel
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Initiating Coverage with an OUTPERFORM Rating and $19 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R